THERAPEUTIC DRUG MONITORING OF INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES: REAL-LIFE DATA IN A COHORT OF PATIENTS

被引：0
|
作者：
Martin Lopez, M. [1 ]
Molina Esteban, N. [1 ]
Cabrera, O. [2 ]
Pablos, J. L. [1 ]
机构：
[1] Hosp Univ 12 Octubre, Inst Invest i12, Rheumatol, Madrid, Spain
[2] Hosp Univ 12 Octubre, Immunol, Madrid, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Spondyloarthritis; bDMARD; Rheumatoid arthritis;
D O I：
10.1136/annrheumdis-2023-eular.4892
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0964
引用
收藏
页码：1700 / 1701
页数：2
相关论文
共 50 条
  • [41] Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study
    Alexandre Dumusc
    Fahad Alromaih
    Matthieu Perreau
    Thomas Hügle
    Pascal Zufferey
    Diana Dan
    Arthritis Research & Therapy, 25
  • [42] Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases
    Gentileschi, Stefano
    Barreca, Cristiana
    Bellisai, Francesca
    Biasi, Giovanni
    Brizi, Maria Giuseppina
    De Stefano, Renato
    Fabbroni, Marta
    Fioravanti, Antonella
    Frati, Elena
    Selvi, Enrico
    Vitale, Antonio
    Cantarini, Luca
    Frediani, Bruno
    Galeazzi, Mauro
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (10) : 1311 - 1312
  • [43] Real-life infliximab trough levels among inflammatory bowel disease patients on maintenance therapy: should we redefine therapeutic range based on inflammatory load?
    Lobaton, T.
    Canete, F.
    Teniente, A.
    Cabre, E.
    Manosa, M.
    Martinez, E.
    Domenech, E.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S366 - S367
  • [44] Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease
    Gil Candel, Mayte
    Gascon Canovas, Juan Jose
    Urbieta Sanz, Elena
    Gomez Espin, Rosa
    Nicolas de Prado, Isabel
    Iniesta Navalon, Carles
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2020, 112 (05) : 360 - 366
  • [45] Proactive Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease Patients Receiving Infliximab and Biosimilars
    Aktay, Atiye
    Odolil, Abel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (12S): : S21 - S21
  • [46] Oral glucocorticoids Therapeutic use and treatment monitoring in inflammatory rheumatic diseases
    Freier, D.
    Strehl, C.
    Buttgereit, F.
    HAUTARZT, 2020, 71 (02): : 139 - 153
  • [47] Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease
    Gibson, David J.
    Ward, Mark G.
    Rentsch, Clarissa
    Friedman, Antony B.
    Taylor, Kirstin M.
    Sparrow, Miles P.
    Gibson, Peter R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (06) : 612 - 628
  • [48] Real-life isoniazid and rifampicin plasma concentrations in children: a tool for therapeutic drug monitoring of tuberculosis
    Chiara Tersigni
    Giulia Boiardi
    Lorenzo Tofani
    Elisabetta Venturini
    Carlotta Montagnani
    Barbara Bortone
    Leila Bianchi
    Elena Chiappini
    Maria Iris Cassetta
    Stefania Fallani
    Andrea Novelli
    Luisa Galli
    BMC Infectious Diseases, 21
  • [49] Real-life isoniazid and rifampicin plasma concentrations in children: a tool for therapeutic drug monitoring of tuberculosis
    Tersigni, Chiara
    Boiardi, Giulia
    Tofani, Lorenzo
    Venturini, Elisabetta
    Montagnani, Carlotta
    Bortone, Barbara
    Bianchi, Leila
    Chiappini, Elena
    Cassetta, Maria Iris
    Fallani, Stefania
    Novelli, Andrea
    Galli, Luisa
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [50] Therapeutic drug monitoring for immune mediated inflammatory diseases
    Chanchlani, Neil
    Yiu, Zenas Z. N.
    Stamp, Lisa K.
    Day, Andrew S.
    BMJ MEDICINE, 2024, 3 (01):
12345